MGRX

Mangoceuticals, Inc. (MGRX) Risks & Opportunities Analysis (2026)

Invetso Score: 2.7/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Risks

Score: 2.4 (Weak)

Extremely weak liquidity, with a 0.18 current ratio versus better-capitalized peers, raises refinancing and working-capital stress risk if operating cash flow remains volatile.

Negative interest coverage and near-zero net debt suggest limited earnings cushion versus profitable peers, so even modest demand softness could quickly pressure financing access.

The very low debt-to-equity ratio does not offset balance-sheet fragility, because peers with stronger liquidity can absorb shocks and preserve growth investment more reliably.

The negative cash conversion cycle is mathematically distorted by payables timing, but compared with peers it still signals dependence on supplier financing that may not be durable.

Opportunities

Score:

If the company sustains supplier-funding efficiency, working-capital release could support liquidity more than peers, but the benefit is fragile and highly dependent on vendor terms.

Minimal leverage leaves optionality for restructuring or selective financing versus more indebted peers, yet weak coverage limits how much external capital can be raised on favorable terms.

Overall Score

Score:

MGRX’s forward positioning is constrained mainly by severe liquidity weakness and poor coverage, while limited leverage and working-capital optionality provide only modest upside versus peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Mangoceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →